|
For immediate release |
02 July 2024 |
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Block Listing Six Monthly Return
|
Name of applicant: |
ALLIANCE PHARMA PLC |
|||
|
Names of schemes: |
a) The Alliance Pharma plc Approved Share Option Plan 2005 b) The Alliance Pharma plc Share Option Plan 2006 c) The Alliance Pharma plc Company Share Option Plan 2015 d) The Alliance Pharma plc Long-Term Incentive Plan 2019 |
|||
|
Period of return: |
From: |
28 December 2023 |
To: |
28 June 2024 |
|
Number of securities originally admitted at date of admission: |
25,000,000 ordinary shares of 1p each 28 June 2017 |
|||
|
Balance of unallotted securities under schemes from previous return: |
a) 57,922 b) 2,473,507 c) 9,572,622 d) 1,115,498 |
|||
|
Plus: The amount by which the block schemes have been increased since the date of the last return (if any increase has been applied for): |
a) Nil b) Nil c) Nil d) Nil |
|||
|
Less: Number of securities issued/allotted under schemes during period: |
a) 57,922 b) 30,496 c) Nil d) 87,041
|
|||
|
Equals: Balance under schemes not yet issued/allotted at end of period: |
a) Nil b) 2,443,011 c) 9,572,622 d) 1,028,457 |
|||
|
Name of contact: |
Chris Chrysanthou, Company Secretary |
|
Telephone number of contact: |
Tel. +44 (0)1249 705166 |
For further information:
|
Alliance Pharma plc |
+ 44 (0)1249 466966 |
|
Head of Investor Relations: Cora McCallum |
+ 44 (0)1249 705168 |
|
|
|
|
|
|
|
Burson Buchanan |
+ 44 (0)20 7466 5000 |
|
Mark Court / Sophie Wills |
|
|
|
|
|
|
|
|
Deutsche Numis (Nominated Adviser and Joint Broker) |
+ 44 (0)20 7260 1000 |
|
Nominated Adviser: Freddie Barnfield / Duncan Monteith / Sher Shah |
|
|
|
|
|
Investec Bank plc (Joint Broker) |
+ 44 (0)20 7597 5970 |
|
Patrick Robb / Maria Gomez de Olea |
|
About Alliance
Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.
We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.
Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands. For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
